Download PDF
Thromb Haemost 2004; 91(03): 420-422
DOI: 10.1055/s-0037-1614285
Editorial Focus
Schattauer GmbH

TAFI: a promising drug target?

Andreas Zirlik
1   Brigham and Women’s Hospital, Harvard Medical School, Cardiovascular Medicine, Boston, Massachusetts, USA
› Author Affiliations
Further Information

Publication History

Received 16 December 2003

Accepted after revision 14 January 2004

Publication Date:
15 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Campbell W, Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun 1989; 162: 933-39.
    CrossrefPubMedGoogle Scholar
  • 2 Hendriks D, Scharpe S, van Sande M. et al. Characterization of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989; 27: 277-85.
    PubMedGoogle Scholar
  • 3 Eaton DL, Malloy BE, Tsai SP. et al. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-38.
    PubMedGoogle Scholar
  • 4 Wang W, Hendricks DF, Scharpe SS. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269: 15937-44.
    PubMedGoogle Scholar
  • 5 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin activatable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
    CrossrefPubMedGoogle Scholar
  • 6 Bajzar L, Morser J, Nesheim ME. TAFI, or procarboxypeptidase B, couples the coagulation and fibrinolyic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-08.
    CrossrefPubMedGoogle Scholar
  • 7 Wang W, Boffa MB, Bajzar L. et al. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
    CrossrefPubMedGoogle Scholar
  • 8 Butenas S, Mann KG. Blood coagulation. Biochemistry (Mosc) 2002; 67: 3-12.
    CrossrefPubMedGoogle Scholar
  • 9 Rijken DC, Sakharov DV. Basic principles in thrombolysis: Regulatory role of plasminogen. Thromb Res 2001; 103S: 41-49.
    PubMedGoogle Scholar
  • 10 Guimaraes AHC, Rijken DC. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in internal clot lysis model. Thromb Haemost 2004; 91: 473-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI dependent. Blood 1996; 88: 2093.
    PubMedGoogle Scholar
  • 12 Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolyic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14477.
    CrossrefPubMedGoogle Scholar
  • 13 Redlitz A, Tan AK, Eaton DL. et al. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
    CrossrefPubMedGoogle Scholar
  • 14 Mutch NJ, Moore NR, Wang E. et al. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. J Thromb Haemost 2003; 01: 2000-07.
    CrossrefPubMedGoogle Scholar
  • 15 Bell WR. Therapeutic Agents - Pharmacokinetics and pharmacodynamics. Rev Cardiovasc Med 2002; 3S: 34-44.
    PubMedGoogle Scholar
  • 16 Nordt TK, Bode C. Thrombolysis: newer thrombolytic agents and their role in clinical medicine. Heart 2003; 89: 1358-62.
    CrossrefPubMedGoogle Scholar
  • 17 GUSTO III Investigators. A comparison of reteplase or acute myocardial infarction. N Engl J Med 1997; 337: 1118-23.
    CrossrefPubMedGoogle Scholar
  • 18 ASSENT-2 Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354: 716-22.
    CrossrefPubMedGoogle Scholar
  • 19 InTIME-II Investigators. Intravenous NPA for the treatment of infarcting myocardium early: InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000; 21: 2005-13.
    CrossrefPubMedGoogle Scholar
  • 20 Tebbe U, Michels R, Adgey J. et al. Randomized double blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence trial. Comparison trial of saruplase and streptokinase (COMPASS) investigators. J Am Coll Cardiol 1998; 31: 487-93.
    CrossrefPubMedGoogle Scholar
  • 21 Herrmann HC, Moliterno DJ, Ohmann EM. et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED trial. J Am Col Cardiol 2000; 36: 1489-96.
    CrossrefPubMedGoogle Scholar
  • 22 GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with firbrinolytic therapy or combination reduced fibrinolytic herapy and platelet glycoprotein Iib/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357: 1905-14.
    CrossrefPubMedGoogle Scholar
  • 23 Fujise K, Revelle BM, Stacy L. et al. A tissue plasminogen activator/P-selectin fusion protein is an effective thrombolytic agent. Circulation 1997; 95: 715-22.
    CrossrefPubMedGoogle Scholar
  • 24 Runge MS, Harker LA, Bode C. et al. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons. Circulation 1996; 94: 1412-22.
    CrossrefPubMedGoogle Scholar
  • 25 Minnema MC, Friedrich PW, von Levi M. et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 1998; 101: 10-4.
    CrossrefPubMedGoogle Scholar
  • 26 Klement P, Liao P, Bajzar L. A novel approach to arterial thrombolysis. Blood 1999; 94: 2735-43.
    PubMedGoogle Scholar
  • 27 Nagashima M, Werner M, Wang M. et al. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb Res 2000; 98: 333-42.
    CrossrefPubMedGoogle Scholar
  • 28 Refino CJ, Schmitt D, Pater C. et al. Carboxypeptidase inhibitor markedly improves the potency of tPA in vivo. Fibrinolysis Proteolysis 1998; 12: 29.
    PubMedGoogle Scholar
  • 29 Mattson C, Bjorkmann JA, Abrahamsson T. et al. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran). Thromb Haemost 2002; 87: 557-62.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Nagashima M, Yin ZF, Zhaou L. et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002; 109: 101-10.
    CrossrefPubMedGoogle Scholar
  • 31 Swaisgood CM, Schmitt D, Eaton D. et al. In vivo regulation of plasminogen function by plasma carboxypeptidase B. J Clin Invest 2002; 110: 1275-82.
    CrossrefPubMedGoogle Scholar
  • 32 Mosnier LO, von dem Borne PAK, Meijers JCM. et al. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact pathway of intrinsic coagulation. Thromb Haemost 1998; 80: 829-35.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fbrinolysis inhibitor and the risk of deep vein thrombosis. Blood 2000; 95: 2855-59.
    CrossrefPubMedGoogle Scholar
  • 34 Yano Y, Kitagawa N, Gabazza EC. et al. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J Clin Endocrinol Metab 2003; 88: 736-41.
    CrossrefPubMedGoogle Scholar
  • 35 Aubert H, Frere C, Aillaud MF. et al. Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. J Thromb Haemost 2003; 01: 791-97.
    CrossrefPubMedGoogle Scholar
  • 36 Montaner J, Ribo M, Monasterio J. et al. Thrombin-activatable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 2003; 34: 1038-40.
    CrossrefPubMedGoogle Scholar
  • 37 Morange PE, Juhan-Vague I, Scarabin PY. et al. Association between TAFI antigen and Ala14Thr polymorphism of the TAFI gene and the angina pectoris incidence. Thromb Haemost 2003; 89: 554-60.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Silveira A, Schatterman K, Goossens F. et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Juhan-Vague I, Morange PE, Aubert H. et al. Plasma thrombin activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the North and South of Europe. Arterioscler Thromb Vasc Biol 2002; 22: 867-73.
    CrossrefPubMedGoogle Scholar
  • 40 Brouwers GJ, Leebeek FW, Tanck MW. et al. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Thromb Haemost 2003; 90: 92-100.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Te Velde EA, Wagenhaar GTM, Reijerkerk A. et al. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2003; 01: 2087-96.
    CrossrefPubMedGoogle Scholar
  • 42 Myles T, Nishimura T, Yun T. et al. Thrombin activatable fibrinolysis inhibitor: A potential regulator of vascular inflammation. J Biol Chem 2003; 278: 51059-67.
    CrossrefPubMedGoogle Scholar
  • 43 Esmon CT. Inflammation and thrombosis. J Thromb Haemost 2003; 01: 1343-48.
    CrossrefPubMedGoogle Scholar